Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Combination of Supportive Therapy for Chronic Kidney Disease (Observational Study)
ChiCTR2500095367Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canrenoic acid in chronic kidney disease (CKD) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Complete remission rate and Partial response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
canrenoic acid
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500095367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095367.